Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04427787
Title A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Indications

large cell neuroendocrine carcinoma

neuroendocrine tumor

pancreatic endocrine carcinoma

rectum neuroendocrine neoplasm

small intestine neuroendocrine neoplasm

pulmonary neuroendocrine tumor

gastrointestinal neuroendocrine tumor

Therapies

Cabozantinib + Lanreotide acetate

Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.